Biden's First 100 Days in Healthcare: Handling the COVID-19 Pandemic, Prospects for Drug Pricing Reform, and the Notable Lack of an FDA Commissioner

Biden’s First 100 Days in Healthcare: Handling the COVID-19 Pandemic, Prospects for Drug Pricing Reform, and the Notable Lack of an FDA Commissioner

Managed Healthcare Executive April 30, 2021
Peter Wehrwein

The administration gets a A-, B+ on most healthcare matters from Marc Samuels, CEO of ADVI and a member of the MHE editorial advisory board.

Marc Samuels, J.D., M.P.H., CEO spoke recently with Senior Editor Peter Wehrwein about the Biden administration’s healthcare accomplishments during its first 100 days — and also prospects for future action on drug pricing and other healthcare-related matters. ADVI is a strategic advisory services firm in Washington, D.C. Prior to founding ADVI and its predecessor company, HillCo HEALTH, Marc served in President George H.W. Bush’s administration and worked for President George W Bush when he was governor of Texas.

Here are excerpts from a transcript of their conversation that has been edited for clarity and length:

...

Today's Sponsors

Today's Sponsor

Topics: Congress / White House, FDA, Govt Agencies, Healthcare System, Insurance, Interview / Q&A, Patient / Consumer, Pricing / Spending, Provider, Public Health / COVID, Trends

2021-04-30T22:11:29-04:00

Biden’s First 100 Days in Healthcare: Handling the COVID-19 Pandemic, Prospects for Drug Pricing Reform, and the Notable Lack of an FDA Commissioner

Today's Sponsors

Today's Sponsor

Share This Article